Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05406817 · ClinicalTrials.gov registry record · Phase 1
Study of Radiolabeled Revumenib in Adults With Acute Leukemia
A Phase 1 study, sponsored by Syndax Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT05406817 is a Phase 1 study that has completed, run by Syndax Pharmaceuticals. The registered enrollment target is 9 participants.
The verdict
NCT05406817, a Phase 1 study, has completed, sponsored by Syndax Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is an open-label study to evaluate the absorption, metabolism, and excretion (AME) of carbon-14 (\[14C\])-revumenib in participants with acute leukemia.
Interventions
- DRUG Revumenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-08-05 |
| Est. Completion | 2024-11-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05406817
The ClinicalTrials.gov registry entry for NCT05406817 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syndax Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Revumenib is the first listed.
NCT05406817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05406817 about?
NCT05406817 is a clinical study titled "Study of Radiolabeled Revumenib in Adults With Acute Leukemia". This is an open-label study to evaluate the absorption, metabolism, and excretion (AME) of carbon-14 (\[14C\])-revumenib in participants with acute leukemia.
What is the current status of trial NCT05406817?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2022-08-05. Estimated completion is 2024-11-18.
What interventions are being tested in trial NCT05406817?
The interventions under investigation include: Revumenib (DRUG).
Who is sponsoring clinical trial NCT05406817?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.